sitagliptin

This page shows the latest sitagliptin news and features for those working in and with pharma, biotech and healthcare.

Novo’s diabetes pill defeats Merck’s Januvia in trial

achieved the target HbA1c level – 7% or lower – compared to 28% of those treated with sitagliptin after 52 weeks of treatment. ... The drug also hit the mark in the obesity setting, with patients achieving statistically significant and superior

Latest news

FDA’s year-end approvals take annual tally to 46

Merck and Pfizer picked up an FDA approval for SGLT2 inhibitor Steglatro (ertugliflozin) and combinations Steglujan (ertugliflozin and sitagliptin) and Segluromet (ertugliflozin and metformin) for use in adults with type 2
FDA panel backs CV claims for Novo Nordisk's Victoza

Merck &Co failed to win FDA approval for a similar claim for its DPP-4 inhibitor Januvia (sitagliptin) in April.
FDA won't add outcomes data to Januvia label

The US regulator has sent the pharma company a complete response letter for DPP-4 inhibitor Januvia (sitagliptin) and combination product Janumet (sitagliptin plus metformin) - along with extended release formulations - saying
Merck & Co and Pfizer take aim at diabetes with trio of new drugs

The marketing applications – filed in the US and EU – cover ertugliflozin as a monotherapy, a fixed-dose combination of ertugliflozin and Januvia (sitagliptin), and a fixed-dose combination of the SGLT2
EU clears AZ's FDA-rejected diabetes combination

The heart failure warning is particularly troublesome for AZ as it does not extend to Merck's top-selling DPP-4 inhibitor Januvia (sitagliptin), which is also being combined with SGLT2 ... A clean label suggests that sitagliptin/ertugliflozin will mount

More from news
Approximately 9 fully matching, plus 98 partially matching documents found.

Latest Intelligence

Market dynamics, marketing and analytics

The dotted horizontal line denotes market growth. The vertical dotted line indicates market leadership where Sitagliptin (Januvia) is the clear winner that is no longer growing at the speed of the
Interview: Christopher Boulton, AstraZeneca

sitagliptin) and Bristol-Myers Squibb (BMS), the original marketers of diabetes standard metformin under the brand name Glucophage.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Delivery Manager/ Head of Delivery – Executive Search: Neg

Home based, Editorial Team Leader, Medical Communications: Excellent package

Business Unit Head, Medical Communications, London: Excellent package

Account Manager, Medical Communications and Marketing: £30, 000 – £40, 000 benefits and bonus

Account Manager: £40, 000 - £45, 000 benefits

Account Director, Consumer Healthcare PR, Global PR agency: £50, 000 – £58, 000

Head of Market Access - International - Based Cambridge: Excellent Basic, Bonus and Flex Benefits

Home based, Principal Medical Writer, Medical Communications: Excellent package

Home based, Chief Medical Writer, Medical Communications: Excellent package

Strategic Planner, Healthcare Advertising: £47, 000 – £53, 000

Senior Medical Writer, Healthcare Advertising Agency: £45, 000 – £50, 000

Client Services Director - Med Comms: Great salary and bebefits

Editorial Director – Medical Education (MedComms): Neg

Client Services Director – Healthcare Advertising - London: Neg

Senior Project Manager - Medical Writing: Great salary and bebefits

Home based, Senior Medical Writer, Medical Communications: Excellent package

Healthcare PR Director: £100, 000 – £120, 000 benefits

Senior Account Manager: Competitive salary commensurate with experience

Scientific Communications Director - Oncology – In House Pharma ...: Neg

Principal Medical Writer / Editorial Director – Medical Communic...: £60, 000 - £80, 000

Account Director, Medical Communications: C£50 – 65, 000 benefits and bonus

Subscribe to our email news alerts

PMHub

Add my company

Research Partnership

We are one of the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the...

Latest intelligence

Developing advocacy in the pharmaceutical industry.: The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?: Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?: The modern approach to B2B sales is data-driven, and enabled by digital tools....